Why is Erasca stock sliding today?

Erasca (ERAS) stock fell 4.9% to $14.375 after HC Wainwright widened its FY2027-FY2030 loss forecasts. Leerink initiated coverage with an Outperform rating and $35 target, but the positive outlook was overshadowed by the downgrade and insider selling. The broader market decline also contributed to the sell-off.

Original reporting
Published Nov 17, 2026, 4:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 4:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$ERAS
Bearish
high confidence
Mentioned
$ERAS
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ERASBearishMed
01

Why it matters

The immediate catalyst is HC Wainwright materially lowering loss estimates across FY2027-FY2030, which the article links to today’s ~4.9% decline. A Form 144 filing tied to an insider share sale adds caution, while Leerink’s bullish initiation is not enough to offset the negative revisions.

02

Market read

For ERAS traders, the key decision is whether to fade the dip or wait for stabilization after estimate revisions and insider-sale signals.

03

What to watch

The article does not quantify trial progress or cash runway; traders may be over-weighting estimate revisions versus upcoming clinical milestones and balance-sheet updates.

Relevance 6/10Novelty 5/10Timing: morning trading today, after-hours sentiment likely still reacting

Background

Erasca is a clinical-stage oncology company with an RAS/MAPK pipeline in early trials, so valuation is highly sensitive to modeled cash burn and financing conditions.

Company-level read

Ticker impact

$ERASBearishHigh confidence
Context

Erasca shares fell nearly 4.9% after HC Wainwright cut multi-year per-share loss estimates and widened FY2027 loss forecast to $0.90.

Expected impact

Likely further pressure or choppy trading as the market reprices the company’s burn trajectory despite a separate bullish initiation.

Evidence & confidence

The article ties the same-day drop directly to Wainwright’s revised loss forecasts and notes additional caution from a Form 144 insider sale filing.

Market effects

Clinical-stage biotechs may trade with higher sensitivity to cash-burn expectations and analyst loss-model revisions.

US broad indices down modestly, reinforcing a risk-off backdrop for unprofitable growth names.

US-focused risk sentiment and AI-chip export headlines are cited as contributing to broader market weakness, indirectly weighing biotech risk appetite.

Counterpoint

Leerink’s Outperform initiation with a $35 target could attract dip-buyers if investors view Wainwright’s cuts as conservative modeling rather than deteriorating fundamentals.

Key entities

  • Erasca

    Clinical-stage oncology company whose shares fell nearly 4.9% on analyst estimate cuts and insider-selling signals.

  • HC Wainwright

    Lowered multi-year per-share loss estimates, widening FY2027 loss forecast from $0.58 to $0.90.

  • Leerink Partners

    Initiated coverage with an Outperform rating and a $35 price target.

  • Form 144

    Indicates a pending insider share sale disclosed on November 16, contributing to cautious positioning.

Related articles

Low

Tango and Erasca’s Phase I/II trial of ERAS-0015 combo opens for enrolment

Tango Therapeutics and Erasca began a Phase I/II trial for ERAS-0015 and vopimetostat combo in lung and pancreatic cancer patients. The trial, sponsored by Tango, aims to find the max tolerated dose and assess safety, tolerability, and antitumour activity. Both companies believe the combo shows promise in treating RAS-driven cancers. ERAS-0015 targets RAS signalling, while vopimetostat inhibits PRMT5.

$ERASHighAI 8/10

FDA Fast Track Puts Erasca’s (ERAS) Pancreatic Bet Center Stage

Erasca (ERAS) received FDA Fast Track Designation for ERAS-0015, an oral pan-RAS molecular glue, for metastatic pancreatic cancer. The designation allows for accelerated regulatory review. In a Phase 1 trial, ERAS-0015 showed a 57% response rate in pancreatic cancer patients. The company plans to initiate pivotal trials in 2027. Q2 2026 R&D expenses rose to $35.9M, and net loss widened to $44.1M. Erasca raised $632.5M in July 2026, leaving it with $384.3M in cash.

$ERASHighAI 8/10

ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death

Erasca, Inc. (ERAS) shares dropped nearly 40% after-hours following a treatment-related death in a Phase 1 study of its cancer therapy ERAS-0015, despite positive early tumor response rates. The patient, a 66-year-old with pancreatic cancer, died after developing pneumonitis. The company reported strong response rates in lung and pancreatic cancers and plans to advance to expansion studies. Additionally, Erasca faces patent infringement allegations from Revolution Medicines regarding ERAS-0015.